Cooperative effects of tumor necrosis factor-alpha and 1,25-dihydroxyvitamin D3 on growth inhibition, differentiation, and c-myc reduction in human promyelocytic leukemia cell line HL-60.
The simultaneous addition of recombinant human tumor necrosis factor-alpha (rTNF-alpha) and 1,25-dihydroxyvitamin D3 (1,25-(OH)2D3) synergistically induced growth inhibition and differentiation of the human promyelocytic leukemia cell line HL-60. A significantly greater reduction in c-myc mRNA level was also observed after a 20-h combined treatment with rTNF-alpha and 1,25-(OH)2D3 than was observed following administration of either agent alone. These results suggest that rTNF-alpha and 1,25-(OH)2D3 induce HL-60 cell growth inhibition through different molecular mechanisms, and that their simultaneous administration could provide a new approach to the treatment of cancer.